---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-057047"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:50:00.553286+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Tempest Q1 2024 net loss $7.9M ($0.36/sh); advancing TPST-1120 to pivotal Phase 3

## Summary
- Cash $32.3M at March 31, 2024; expects runway into Q2 2025.
- Net loss $7.9M ($0.36/sh) vs $7.6M ($0.55/sh) YoY; R&D $4.3M, G&A $3.6M.
- TPST-1120 plans to advance to pivotal Phase 3 in first-line HCC, subject to FDA feedback.
- TPST-1495 planned for Phase 2 in FAP in 2024 under NCI funding; updated data expected in 2024.

## SEC filing metadata
- accession: 0000950170-24-057047
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000095017024057047/0000950170-24-057047-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000095017024057047/tpst-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-057047
- JSON: https://secwatch.observer/filing/0000950170-24-057047.json
- Plain text: https://secwatch.observer/filing/0000950170-24-057047.txt

## Key facts
- Earnings Releases
  Tempest Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $7.9 million, EPS $0.36.
  - Period: the quarter ended March 31, 2024
  - Net income: $7.9 million
  - EPS: $0.36
  - Result: reported results
  source text: Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class i targeted and immune-mediated therapeutics to fight cancer, today reported financial results for the quarter ended March 31, 2024, and provided a corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1544227/000095017024057047/0000950170-24-057047-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.